BOTULINUM TOXIN EFFECTIVENESS IN PRIMARY HYPERHIDROSIS PATIENTS

TINATIN GHIBRADZE; TINA KITUASHVILI; MARINA LOMIDZE

doi:10.52340/jecm.2021.563

BOTULINUM TOXIN EFFECTIVENESS IN PRIMARY HYPERHIDROSIS PATIENTS

Authors

TINATIN GHIBRADZE
TINA KITUASHVILI
MARINA LOMIDZE

DOI:

https://doi.org/10.52340/jecm.2021.563

Keywords:

botulinum toxin, primary axillary hyperhidrosis

Abstract

Hyperhidrosis represents pathology of eccrine sweat glands and is manifested by the skin excessive sweating. For patients, living along with hyperhidrosis represents a big challenge, which has a significant impact on numerous aspects of everyday life, as well as on the social and professional lifestyle and psycho-emotional health.

Downloads

Download data is not yet available.

References

Schmid G, Steen T. “Skin disorders and quality of life” International encyclopedia of rehabilitacion, 2012.

www. MedicineNet.com “Definition of chronic disease”, 2012.

Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 2016 Dec; 75 (6): 1126-33.

Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and Disease Burden of Hyperhidrosis in the Adult Population. Dermatology. 2013; 227 (1): 10–3.

Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence andseverityin the United States. Arch Dermatol Res. 2016 Dec 15; 308 (10): 743–9.

Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and Characteristics of Hyperhidrosis in Sweden: A Cross-Sectional Study in the General Population.Dermatology 2016; 232 (5): 586–91.

Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan: From questionnaire analysis. J Dermatol. 2013 Nov; 40 (11): 886-90.

Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology (Third ed.), Elsevier Saunders. 2012; Vol 1: 587-602.

De Paula Loureiro M, de Campos JRM, Wolosker N, Kauffman P. Hyperhidrosis A Complete Guide to Diagnosis and Management. Book-2018. 281p.

Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients’ daily life and quality of life: A qualitative investigation. Health Qual Life Outcomes. 2017; 15(1): 1–10.

Lenefsky M, Rice ZP. Hyperhidrosis and its impact on those living with it. Am J Manag Care. 2018; 24 (23): S491–5.

Lowe A. N. J, Bodokh et al, Campanati I. “The place of botulinum toxin type A in the treatment of focal hyperhidrosis,” British Journal of Dermatology, vol. 151, no. 6, 1115–1122, 2004.

Cott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthamol 1973; 12: 924–7.

Greve B, Raulin C, Togel B. Current therapeutic strategies for hyperhidrosis: a review. Eur J Dermatol. 2002; 12: 219-223

A Comprehensive Approach to the Recognition, Diagnosis, and Severity-Based Treatment of Focal Hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee, Dermatologic Surgery, August 2007, 908-923.

Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Derm. 2008 Sep.